Yüklüyor......
Targets of opportunity for precision medicine
In this issue of Blood, Schinke et al have identified a higher expression of CXCR2 in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) stem cells than in normal hematopoietic stem cells (HSCs) and demonstrated preclinical therapeutic proof of principle.(1)
Kaydedildi:
| Yayımlandı: | Blood |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4432001/ https://ncbi.nlm.nih.gov/pubmed/25977578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-04-638270 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|